It is recognized that a higher level of c-Myc is closely correlated with chemotherapy resistance in many cancers, such as prostate cancer, ovarian cancer, melanoma, lung cancer, and hepatocellular carcinoma [100,101,102,103]. This evidence concerns the gene MYC and prostate carcinoma.